Biotech

All Articles

Amgen reports very first phase 3 gain for $400M chronic eczema drug

.Amgen has discussed (PDF) the very first period 3 records on its own $400 thousand chronic eczema d...

Biogen, UCB file period 3 lupus succeed after falling short earlier test

.Biogen and also UCB's rely on developing into period 3 astride a broken research study hopes to hav...

Aptadir really hopes brand-new RNA preventions can turn around difficult cancers

.Italian biotech Aptadir Therapies has actually introduced with the guarantee that its own pipeline ...

Wave surfs DMD results to regulatory authorities' doors, sending out stockpile

.Surge Life Sciences has satisfied its own goal in a Duchenne muscle dystrophy (DMD) study, installi...

Sanofi tweezes new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, using up the...

Achilles drops tissue treatment plan, supports for layoffs after skipping 'industrial feasibility' targets

.Achilles Therapies has actually destroyed its own technique. The English biotech is actually knocki...

Aligos proclaims stage 2 MASH gain, reducing liver body fat approximately 46%

.Aligos Therapeutics is actually heralding a midstage win in metabolic-dysfunction connected steatoh...

Basilea ratings $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's job developing brand-new antifungals has obtained a notable boost from the ...

Capricor offers Europe rights to late-stage DMD treatment for $35M

.Having actually scooped up the USA civil liberties to Capricor Rehabs' late-stage Duchenne muscle d...

FDA fragments adcomm for Applied's uncommon ailment medication

.After pushing the choice meeting for Applied Therapies' metabolic ailment drug govorestat, the FDA ...